Hematologic Malignancy Branch & Department of Laboratory Medicine, Center for Clinical Services, Goyang, Korea.
J Gynecol Oncol. 2009 Dec;20(4):243-5. doi: 10.3802/jgo.2009.20.4.243. Epub 2009 Dec 28.
The aim of the current study is to test whether immortalized B-lymphocyte cell line via Ebstein-Barr virus (EBV) transformation is feasible and can be an unlimited source of genome wide study.
We obtained peripheral whole blood from 5 ovarian cancer patients and immortalized the B-cell lines using EBV transformation. The success rate was analyzed and the bio-identity of the genome was performed using human leukocyte antigen (HLA) identity test.
EBV transformation was successful in all 5 cases (95% confidence interval, 46.3% to 100%). After cryopreservation of EBV-transformed B-cell lines and subsequent thawing, we observed that all cell lines were viable and proliferative. To check bio-identity, HLA-A, B, and DR were tested between the genome of the original samples and the transformed samples. The HLA typing revealed that all observed HLA-A, B, and DR type was identical in 5 cases before and after EBV-transformation.
The current results suggest that EBV-transformation of peripheral blood is an efficient tool in genome banking. The EBV-transformed B-cell lines may be a valuable resource of genome in multi-center translational research by the Korean Gynecologic Oncology Group.
本研究旨在验证通过 Epstein-Barr 病毒（EBV）转化的永生 B 淋巴细胞系是否可行，并能否成为全基因组研究的无限来源。
我们从 5 名卵巢癌患者中获得外周全血，并使用 EBV 转化来永生化 B 细胞系。分析成功率，并使用人类白细胞抗原（HLA）鉴定测试进行基因组的生物同一性检测。
EBV 转化在所有 5 例中均成功（95%置信区间，46.3%至 100%）。在 EBV 转化的 B 细胞系冷冻保存和随后解冻后，我们观察到所有细胞系均具有活力和增殖性。为了检查生物同一性，在原始样本和转化样本的基因组之间测试了 HLA-A、B 和 DR。HLA 分型显示，在 EBV 转化前后的 5 例中，所有观察到的 HLA-A、B 和 DR 型均相同。
目前的结果表明，外周血的 EBV 转化是基因组库存储的有效工具。EBV 转化的 B 细胞系可能成为韩国妇科肿瘤学组多中心转化研究中基因组的宝贵资源。
